Alimera Sciences Inc (ALIM): Price-to-Revenue Ratio

Symbol and logo of brand Alimera Sciences (ALIM)

Alimera Sciences management has successfully established a global distribution network, which has expanded operating profit. The company's historical P/S ratio demonstrates this trend, where 2.90 reflects the metric's baseline. Growth is supported by the brand's authority in ophthalmology and physician confidence in implants. Niche dominance in the therapy of diabetic macular edema allows the company to maintain premium pricing power.

Alimera Sciences Inc (ALIM): Price-to-Revenue Ratio from 07/04/2022 to 09/21/2024

Metric breakdowns and analytics for Alimera Sciences (ALIM)

- stock value and consensus price forecast:
Stock Price alimerasciences.com|ALIM - Price Target Chart
- stock exchange capitalization data:
Market Value Alimera|ALIM - Enterprise Value
- issuer book value statistics:
Net Assets per Share Alimera Sciences|ALIM - Company Book Value|Market Cap to Net Assets Ratio alimerasciences.com|ALIM - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Alimera Sciences|ALIM - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital alimerasciences.com|ALIM - Company Aggregate Debts|Debts to Book Capitalization Alimera|ALIM - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Alimera Sciences|Interim Coverage Ratio alimerasciences.com
- net income and valuation ratios data:
ALIM - Net Profit|Future Profit Alimera Sciences|ALIM - P/E Multiple|Market Cap to Projected Earnings alimerasciences.com|ALIM - PEG Multiple|Company Value to EBITDA Alimera|ALIM - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Alimera Sciences|ALIM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months alimerasciences.com|ALIM - Earnings growth in current year|Expected net earnings per share growth next year Alimera Sciences
- total revenue and sales volume data:
ALIM - Company Revenue|Company Future Sales alimerasciences.com|ALIM - P/S Multiple|Forward P/S Multiple Alimera
General company analysis:ALIM Alimera Sciences Inc
Mass-produced product of Alimera Sciences, Inc.

The P/S ratio compares market capitalization to annual revenue, promptly reflecting shifts in market expectations regarding business scale. This indicator determines the value per unit of sales, helping to identify asset overheating in a timely manner and avoid speculative risks. For Alimera Sciences (ALIM), with its exclusive patents for ophthalmological implants, the P/S business valuation confirms the premium nature of the revenue generated by the absence of competitors.

Who Alimera Sciences competes with

P/S Multiple alcon.com (ALC)|Price-to-Revenue Ratio Bausch + Lomb BLCO|Glaukos Corp - Price-to-Revenue Ratio|Apellis Pharmaceuticals Inc - P/S Multiple|Price-to-Revenue Coefficient Belite Bio, Inc BLTE|Ocular Therapeutix (OCUL) - Price-to-Revenue Ratio|Market Cap to Revenue harrowinc.com|VRDN (Viridian Therapeutics, Inc.) - P/S Multiple|Price to Sales LENZ Therapeutics Inc LENZ|Price-to-Revenue Ratio Oculis AG (OCS)|EYPT (EyePoint Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple KOD (Kodiak Sciences Inc.)|P/S Multiple Aldeyra Therapeutics Inc. ALDX|KALA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IRD (Opus Genetics Inc)|okyopharma.com (OKYO) - Price-to-Revenue Ratio|ADVM - Price-to-Revenue Coefficient|OTLK (Outlook Therapeutics) - P/S Multiple|Market Cap to Revenue clearsidebio.com (CLSD)|P/S Multiple NBY|Price-to-Revenue Coefficient kiorapharma.com|P/S Multiple EYEN (Eyenovia)|Guardion Health (GHSI) - Price to Sales|OCUP - Price-to-Revenue Ratio|OPT (opthea.com) - Market Cap to Revenue Ratio